Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily
Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant …

RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged≥ 65 years …

Covalent drugs have made a major impact on human health but until recently were shunned
by the pharmaceutical industry over concerns about the potential for toxicity. A resurgence …

Background Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared
with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in …

Within druggable target space, new small-molecule modalities, particularly covalent
inhibitors and targeted degraders, have expanded the repertoire of medicinal chemists …

Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …